首页> 外文OA文献 >Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors

【2h】

Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors

机译：B细胞淋巴瘤非清髓性同种异体骨髓移植后利妥昔单抗和首先基于非HLA因子选择供体的II期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Kanakry Jennifer A.; Gocke Christopher D.; Bolaños-Meade Javier; Gladstone Douglas E.; Swinnen Lode J.; Blackford Amanda L.; Fuchs Ephraim J.; Huff Carol Ann; Borrello Ivan; Matsui William H.; Brodsky Robert A.; Rosner Gary L.; Shanbhag Satish; Luznik Leo; Jones Richard J.; Ambinder Richard F.; Kasamon Yvette L.;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors [J] . Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2015,第12期

机译：B细胞淋巴瘤非清髓性同种异体骨髓移植伴利妥昔单抗的移植及首先基于非HLA因子选择供体的II期研究
2. A Phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with BCell lymphoid malignancies: Favorably durable event-free survival in chemosensitive patients [J] . SauterC.S., BarkerJ.N., LechnerL., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2014,第3期

机译：II期研究：非清髓性同种异体干细胞移植联合利妥昔单抗治疗B细胞淋巴恶性肿瘤：对化学敏感患者的无事件生存期持久
3. Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. [J] . Jordan Gauthier, Xavier Poiré, Anne-Claire Gac, Bone marrow transplantation . 2018,第4期

机译：Hodgkin淋巴瘤患者HLA匹配相关捐赠者的HAPLoidentical更好的结果在霍格金淋巴瘤接受同种异体血糖细胞移植患者 - 通过骨髓移植和细胞疗法的Francophone社会研究。
4. Effect of transplantation of bone marrow mesenchymal stem cells on the expression of nerve growth factor and brain-derived neurotrophic factor in rats after sciatic nerve crush injury [C] . Hua Xin, Guang Yang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：骨髓间充质干细胞移植对坐骨神经挤压伤大鼠神经生长因子和脑源性神经营养因子表达的影响
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Phase II study of non-myeloablative allogeneic bone marrow transplantation for B-cell lymphoma with post-transplantation rituximab and donor selection based first on non-HLA factors [O] . Jennifer A. Kanakry, Christopher D. Gocke, Javier Bolaños-Meade, -1

机译：利妥昔单抗的非清髓性同种异体骨髓移植治疗B细胞淋巴瘤的II期研究和首先基于非HLA因素的供体选择
7. Early Results of a Phase II Study Adding Peri-Transplant Rituximab to Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients (PTS) with High-Risk Fludarabine-Refractory Chronic Lymphocytic Leukemia (Cll) [O] . Sorror M.L., Storer B., Sandmaier B.M., 2012

机译：高风险氟达拉滨难治性慢性淋巴细胞性白血病（Cll）患者（PTS）的非清髓性调节和同种异体造血细胞移植（HCT）的II期研究的早期结果

Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors

著录项

引文网络

相似文献

相关主题

期刊订阅